Introduction {#S1}
============

The circadian system, a set of biological clocks that regulate almost all physiological and behavioral processes, has evolved to adapt the organism's physiology to cyclic environmental changes ([@B1]--[@B4]). In mammals, the master clock resides in the suprachiasmatic nuclei (SCN) of the hypothalamus and is mainly synchronized by the light--dark (LD) cycle ([@B5]). The circadian system also includes peripheral clocks, entrained by the SCN *via* neural and humoral cues, such as rhythmically secreted hormones ([@B6]--[@B8]), and other SCN-independent cues like food ([@B9]).

One of the major physiological processes controlled by the SCN is metabolism, including metabolic rate and circadian rhythms of food intake ([@B3]). Food consumption is normally confined to the wake/active phase, while fasting periods occur during the rest/sleep phase, correlating to the anabolic, and catabolic phases of metabolism, respectively ([@B10]). Alterations of the circadian pacemaker can lead to metabolic pathologies, such as obesity or metabolic syndrome ([@B11]). For example, shift work, chronic forced circadian desynchronization or mutations of clock genes can affect the pattern of food intake and lead to increased levels of circulating triglycerides, and adipose tissue masses resulting in an augmented body weight ([@B12]--[@B15]).

Melatonin is a hormone produced by the pineal gland during the dark phase and is considered one of the most important circadian outputs ([@B16]). It regulates major physiological processes, including the sleep--wake cycle, and lipid and glucose metabolism ([@B17]--[@B22]). The SCN interact with the pineal gland through the sympathetic neurons of the superior cervical ganglia (SCG) ([@B23]). This interaction modulates the arylalkylamine *N*-acetyltransferase (AA-NAT) activity, the main enzyme responsible for melatonin rhythm generation in vertebrates ([@B24]). The elimination of the pineal melatonin rhythm, or a reduction of its amplitude, renders the circadian pacemaker a less self-sustained, often damped, oscillatory system ([@B25]). On the other hand, forced circadian desynchronization induced by an LD cycle of 22 h in rats ([@B26]) or by shift work in humans ([@B27]) disrupts rhythmic melatonin secretion.

The SCG are the uppermost ganglia of the paraventral sympathetic chain and innervate the pineal gland, among others structures ([@B28]). Superior cervical ganglionectomy (SCGx) is a reliable model to study the role of sympathetic innervation on neuroendocrine interactions ([@B29]--[@B31]). Moreover, SCGx has been used to determine the influences of the circadian clock (i.e., the SCN) on neuroendocrine functions. In this sense, SCGx disrupts the circadian system by depressing melatonin secretion and suppressing its rhythm ([@B32], [@B33]), presumably by the inhibition of pineal AA-NAT activity ([@B34]). This also results in an abolition of the rhythmic excretion of urinary 6-sulphatoxymelatonin, a melatonin metabolite ([@B35]). In addition, the SCG also cover other territories such as other glands, brain areas, and the cardiovascular system, which might also be implied in metabolic regulation ([@B36]--[@B41]).

Taking into account that the lack of melatonin can produce circadian alterations, and that sympathetic innervation from the SCG covers diverse neuroendocrine effectors, the aim of our work was to study if SCGx can affect rat metabolism and whether this is related to an impairment of the circadian clock.

Materials and Methods {#S2}
=====================

Ethics Statement {#S2-1}
----------------

All animal procedures were approved by the Institutional Animal Care and Use Committee at the School of Medicine, National University of Cuyo, Mendoza, Argentina (Protocol ID 9/2012) and were conducted in accordance with the National Institutes of Health's Guide for Care and Use of Laboratory Animals and the Animal Research: Reporting *In Vivo* Experiments (ARRIVE) Guidelines.

Animals {#S2-2}
-------

Young (3 months old) male Wistar rats were raised in our colony and maintained in a 12:12 h LD cycle (with zeitgeber time 12---ZT 12---defined as the time of lights off; light intensity averaging 300 lux at the cage level), in a controlled environment with food and water *ad libitum*.

Locomotor Activity Rhythms {#S2-3}
--------------------------

Animals were transferred to individual cages equipped with infrared motion sensors. Locomotor activity was assessed by the interruption of the infrared beam and recorded every 5 min (Archron, Argentina). The locomotor activity rhythm analysis was performed using the "el Temps" program (<http://www.el-temps.com>). Locomotor activity onset was defined as the 10-min bin that contained at least 50% of the maximum activity/bin followed by another bin of at least another 50% of the maximum activity bin within 40 min. Entrainment to the LD cycle was confirmed by periodogram analysis (χ^2^ test). Phase angle was measured as the difference (in minutes) between activity onset and lights off. Total daytime activity was assessed by the area under the curve (AUC) of the waveform of each animal. Activity was expressed as a percentage of the total activity or relative activity by comparing post-surgery activity to the activity counts of the 3 weeks previous to the surgery (pre-surgery) as the post-/pre-ratio.

Surgery {#S2-4}
-------

Bilateral superior cervical ganglionectomy (SCGx) was performed as described by Savastano et al. ([@B31]). Briefly, under ketamine (50 mg/kg of body weight)/xylazine (5 mg/kg of body weight) anesthesia, the ventral neck region was shaved and disinfected. The salivary glands were exposed through a 2.5 cm vertical incision and retracted to uncover the underlying muscles. The carotid bifurcations were identified through the carotid triangles and the SCG were removed after sectioning the sympathetic trunks, the external carotid nerves, and the internal carotid nerves. For sham-operated animals, the same procedure was performed but the ganglia were not removed.

Animal Weight and Food Intake Measurements {#S2-5}
------------------------------------------

Body weight and food consumption were monitored weekly at ZT10. After a 3-week pre-surgery baseline, animals were subjected to bilateral SCGx or a sham procedure (*n* = 9 per group), and body weight and food intake were measured for another 10 weeks. Food efficiency (FE) was analyzed by the body weight/food intake ratio.

The food intake rhythm was analyzed in both groups at week 11. Daytime (i.e., during lights on) and nighttime (during lights off) food intakes were measured daily at the end of the light and dark phases for 10 days (*n* = 5 per group). Daytime and nighttime feedings were expressed as a percentage of total food consumed per day.

Glycemia and Glucose Tolerance Test (GTT) {#S2-6}
-----------------------------------------

At week 10, glycemia was measured at ZT10 using PTS PanelsTM test strips for CardioChekTM Brand Analyzer (Hannover, Germany) (*n* = 9 per group).

At week 13, a GTT was performed after 18 h fast (*n* = 5 per group). Glycemia was measured as mentioned above before and 15, 30, 60, and 120 min after glucose administration (orogastric, 3 g/kg of body weight from a 30% solution of [d]{.smallcaps}-glucose), at ZT10. The AUC of glycemia vs. time was calculated above each individual baseline (basal glycemia).

Fat Weight Measurements {#S2-7}
-----------------------

At the end of week 13, animals were decapitated under anesthesia, and epididymal, retroperitoneal, mesenteric, and inguinal adipose tissues were collected and weighed (*n* = 5 per group). Fat weight was expressed as relative to body weight.

Statistical Analysis {#S2-8}
--------------------

Data were expressed as mean ± SEM and analyzed using PRISM5 (GraphPad Software Inc., La Jolla, CA, USA). Statistical difference between means was determined by Student's *t*-test. For the grouped statistical analysis, two-way ANOVA or repeated measures two-way ANOVA was used with Bonferroni as post-test. *p* \< 0.05 was considered significant and *p* \< 0.01 highly significant.

Results {#S3}
=======

Global Metabolism Is Affected by Bilateral Superior Cervical Ganglionectomy {#S3-1}
---------------------------------------------------------------------------

To study the effect of SCGx on rat metabolism, animals were subjected to ganglionectomy or a sham procedure at the middle of week 3 (*n* = 9 per group). Body weight and food consumption were measured, and FE (body weight/food intake ratio) was calculated. Rats subjected to SCGx did not exhibit differences in body weight (Figure [1](#F1){ref-type="fig"}A) but had significant lower food intake when compared with sham animals (Figure [1](#F1){ref-type="fig"}B), throughout the 10 weeks after surgery. An FE analysis ([@B42]) showed metabolic differences between the two groups. FE was higher in ganglionectomized animals, revealing that these rats gained more body mass per gram of consumed food than controls (Figure [1](#F1){ref-type="fig"}C).

![Bilateral superior cervical ganglionectomy affects metabolic variables. Rats subjected to SCGx at week 3.5 did not exhibit differences in body weight \[**(A)**; repeated measures two-way ANOVA: *p* = 0.0002, *F* = 3.229 for interaction, *p* \< 0.0001, *F* = 1,588 for time, *p* \> 0.05, *F* = 0.008 for surgery; *n* = 9 per group\], but had significant lower food intake throughout the 10 weeks after surgery \[**(B)**; repeated measures two-way ANOVA: *p* \< 0.0001, *F* = 35.51 for interaction, *p* \< 0.0001, *F* = 222.8 for time, *p* = 0.0015, *F* = 14.92 for surgery, followed by Bonferroni post-tests: \*\*\**p* \< 0.001, \*\**p* \< 0.01; *n* = 9 per group\]. A food efficiency (body weight/food intake ratio) analysis demonstrated metabolic differences between the two groups with higher levels in ganglionectomized animals \[**(C)**; repeated measures two-way ANOVA: *p* \< 0.0001, *F* = 42.75 for interaction, *p* \< 0.0001, *F* = 374.7 for time, *p* \< 0.0001, *F* = 76.49 for surgery, followed by Bonferroni post-tests: \*\*\**p* \< 0.001, \**p* \< 0.05; *n* = 9 per group\]. The rats used in this work were still growing from young-to-adulthood and therefore increasing their body mass and food consumption over time. Arrows indicate the day of surgery. Repeated measures two-way ANOVA results are depicted at the bottom right of each figure. Values are given as mean ± SEM.](fendo-08-00370-g001){#F1}

Ganglionectomy Increases Daytime Locomotor Activity {#S3-2}
---------------------------------------------------

Rats subjected to SCGx or sham surgeries (*n* = 9 per group) were placed individually in cages with infrared sensors to study their activity distribution during the day. An activity rhythm analysis demonstrated that entrainment to the LD cycle and activity phase angle were not affected by ganglionectomy (Table [1](#T1){ref-type="table"}; Figure [2](#F2){ref-type="fig"}A). Moreover, SCGx animals did not show differences in the levels of total activity as post-/pre-surgery ratio (Table [1](#T1){ref-type="table"}; Figure [2](#F2){ref-type="fig"}B; SCGx group: 1.08 ± 0.083; sham-operated group: 0.99 ± 0.042; data expressed as mean of post-/pre-surgery ± SEM). However, locomotor activity of ganglionectomized animals during the lights-on phase increased after surgery and remained higher throughout the 10-week post-surgery interval (Figure [2](#F2){ref-type="fig"}C). Moreover, the relation between the AUC of daytime activity after and before surgery was significantly higher in the SCGx animals (Table [1](#T1){ref-type="table"}; Figure [2](#F2){ref-type="fig"}D; SCGx group: 5.492 ± 0.4126; sham group: 1.992 ± 0.2212; data expressed as mean of post-/pre-surgery ± SEM). This increase occurs at the expense of a reduced nighttime activity (Table [1](#T1){ref-type="table"}, SCGx group: 0.91 ± 0.005; sham-operated group: 1.01 ± 0.003; data expressed as mean of post-/pre-surgery ± SEM).

###### 

Effects of SCGx on the diurnal rhythm of locomotor activity.

                                           Sham            SCGx            *p*-Value
  ---------------------------------------- --------------- --------------- -----------
  Period (min)                             1,441 ± 0.645   1,442 ± 1.323   0.522
  Phase angle (min)                        6.50 ± 1.190    7.00 ± 1.080    0.766
  Total activity (post-/pre-surgery)       0.99 ± 0.042    1.08 ± 0.083    0.351
  Daytime activity (post-/pre-surgery)     1.99 ± 0.221    5.49 ± 0.412    \<0.0001
  Nighttime activity (post-/pre-surgery)   1.01 ± 0.003    0.91 ± 0.005    \<0.0001

![Ganglionectomy affects locomotor activity rhythm. **(A)** Representative actograms for animals subjected to SCGx or sham procedure (*n* = 9 per group). Red lines indicate the moments that the system did not record activity. **(B)** A locomotor activity analysis showed no differences in the levels of total activity, as post-surgery/previous-to surgery ratio (SCGx group, 1.08 ± 0.083; sham group, 0.99 ± 0.042; values are given as mean ± SEM; *t*-test: *p* \< 0.353; *n* = 9 per group), but the activity of SCGx animals during daytime (i.e., during lights on) increased after surgery and remained higher throughout the 10-week post-surgery interval \[**(C)**; repeated measures two-way ANOVA: *p* \< 0.0001, *F* = 16.55 for interaction, *p* \< 0.0001, *F* = 11.50 for time, *p* \< 0.0001, *F* = 43.69 for surgery, followed by Bonferroni post-tests: \*\*\**p* \< 0.001; *n* = 9 per group\]. This increased daytime activity is evidenced in the area under the curve (AUC) from post-surgery/pre-surgery ratio, that was significantly higher in the SCGx animals when compared with the sham group \[**(D)**; SCGx group: 5.492 ± 0.4126; sham group: 1.992 ± 0.2212; values are given as mean ± SEM; *t*-test: \*\*\**p* \< 0.0001, *t* = 7.475; *n* = 9 per group\]. Repeated measures two-way ANOVA results are expressed at the bottom right of the figure. Asterisks above the curve indicate significant *p*-values of the Bonferroni post-test. The arrows correspond to the day of surgery.](fendo-08-00370-g002){#F2}

Ganglionectomy Increases Food Intake during Daytime {#S3-3}
---------------------------------------------------

We next studied the daily pattern of food consumption, which can be affected by circadian alterations ([@B13]). Ganglionectomized animals had a lower level of food intake per day (Figure [3](#F3){ref-type="fig"}A; 19.06 ± 0.5960 g for SCGx group; 22.80 ± 0.8027 g for sham group, *n* = 5 per group).

![Daytime feeding is increased in SCGx animals. Ganglionectomized animals had a lower level of food intake \[**(A)**; SCGx group: 19.06 ± 0.5960 g; sham group: 22.80 ± 0.8027 g; values are given as: mean ± SEM; *t*-test: \*\**p* = 0.0057, *t* = 3.738; *n* = 5 per group\]. Feeding rhythm was also affected: daytime (i.e., during lights on) food consumption was higher in SCGx rats \[**(B)**; SCGx group: 16.68 ± 0.9030 g; sham group: 6.160 ± 0.2015 g; *t*-test: \*\*\**p* \< 0.0001, *t* = 11.37; *n* = 5 per group\], and lower during the nighttime (i.e., during lights off) \[**(C)**; SCGx group: 83.48 ± 0.8864 g; sham group: 93.63 ± 0.7122 g; *t*-test: \*\*\**p* = 0.0001, *t* = 8.926; *n* = 5 per group\], compared with sham animals. Values are given as mean ± SEM.](fendo-08-00370-g003){#F3}

As it was observed with the activity rhythm, a food intake rhythm analysis revealed increased food consumption during daytime (Figure [3](#F3){ref-type="fig"}B; 16.68 ± 0.9030 g for SCGx group; 6.160 ± 0.2015 g for sham group), and a slightly but significantly lower feeding activity during the night (Figure [3](#F3){ref-type="fig"}C; 83.48 ± 0.8864 g for SCGx group; 93.63 ± 0.7122 g for sham group).

SCGx Animals Exhibit Lower Basal Levels of Blood Glucose but Higher Adipose Tissue {#S3-4}
----------------------------------------------------------------------------------

Six weeks after surgery, a glycemia analysis at ZT10 showed lower levels of blood glucose in SCGx rats (Figure [4](#F4){ref-type="fig"}A; 48.89 ± 4.464 mg/dl for SCGx group; 78.50 ± 4.392 mg/dl for sham group; *n* = 9 per group).

![SCGx animals exhibit lower basal levels of blood glucose, with normal glucose tolerance. Basal glucose levels at ZT10 were measured at week 10. We found lower levels in SCGx rats when compared with the sham ones \[**(A)**; SCGx group: 48.89 ± 4.464 mg/dl; sham group: 78.50 ± 4.392 mg/dl; *t*-test: \*\*\**p* = 0.0003, *t* = 4.706; *n* = 9 per group\]. At week 13, a glucose tolerance test (GTT) was performed (*n* = 5 per group). Glycemia was measured before and 15, 30, 60, and 120 min after glucose administration. There were no differences in glycemia kinetics **(B)** or in the area under the curve of the GTT \[**(C)**; SCGx group: 935 ± 57.04 mg/dl; sham group: 1,008 ± 65.66 mg/dl; *t*-test: *p* = 0.214, *t* = 0.834; *n* = 5 per group\] between ganglionectomized and sham animals. Values are given as: mean ± SEM. Repeated measures two-way ANOVA results are shown at the right of the figure.](fendo-08-00370-g004){#F4}

At week 13, a GTT was performed (*n* = 5 per group). Surprisingly, there were no differences in glycemia kinetics (Figure [4](#F4){ref-type="fig"}B) or in the AUC of the GTT (Figure [4](#F4){ref-type="fig"}C; 935 ± 57.04 mg/dl for SCGx; 1,008 ± 65.66 mg/dl for sham) between ganglionectomized and sham animals.

Finally, to better understand the increased body mass in SCGx animals, we studied the fraction of the body weight that is represented by adipose tissue. For this, we measured the levels of mesenteric, epididymal, retroperitoneal, and total fat at the end of week 13 (Figure [5](#F5){ref-type="fig"}), and found adipose tissue significantly increased in SCGx when compared with sham animals (epididymal fat: SCGx group, 0.0186 ± 0.0005; sham group, 0.0162 ± 0.0004; retroperitoneal fat: SCGx group, 0.0154 ± 0.0002; sham group, 0.0130 ± 0.0007; mesenteric fat: SCGx group, 0.002 ± 0.0003; sham group, 0.002 ± 0.0003; total fat: SCGx group, 0.0362 ± 0.0007; sham group, 0.0318 ± 0.0011; *n* = 5 per group).

![Ganglionectomized rats exhibit higher levels of adipose tissue. Epididymal + inguinal (Epi + Inguinal), retroperitoneal, and mesenteric fat were collected at the end of week 13, and their weights were relativized to body weight for each animal. Fat tissue was significantly increased in SCGx compared with sham animals (for epididymal + inguinal fat, SCGx group: 0.0186 ± 0.0005; sham group: 0.0162 ± 0.0004; *t*-test: \*\**p* = 0.0053, *t* = 3.795; for retroperitoneal fat, SCGx group: 0.0154 ± 0.0002; sham group: 0.0130 ± 0.0007071; *t*-test: \**p* = 0.0125, *t* = 3.207, for mesenteric fat, SCGx group: 0.002 ± 0.0003; sham group: 0.002 ± 0.0003; *t*-test: *p* = 1, *t* = 0; and for total fat, as the collective weight of epididymal + inguinal, retroperitoneal, and mesenteric fat, SCGx group: 0.0362 ± 0.0007; sham group: 0.0318 ± 0.0011; *t*-test: \*\**p* = 0.0032, *t* = 4.14; values are given as: mean ± SEM; *n* = 5 per group).](fendo-08-00370-g005){#F5}

Discussion {#S4}
==========

The impact of the superior cervical ganglionectomy (SCGx) on hormone secretion, and blood glucose and insulin release has been reported before ([@B40], [@B43]--[@B46]) but its role on body weight homeostasis remains to be fully established. In this work, we assessed the impact of SCGx on rat metabolism and diurnal rhythms. Rats subjected to SCGx showed: (1) increased FE (i.e., gained more weight per gram of food consumed); (2) increased activity during the lights-on phase of the photoperiod; (3) increased feeding during daytime; (4) reduced glucose levels, without changes in glucose tolerance, at ZT10; and (5) increased adipose tissue mass.

The SCG provide sympathetic innervation to diverse areas including the hypothalamus, the pineal gland, cephalic blood vessels, the choroid plexus, the eye, the myocardium, the salivary and thyroid glands, and the carotid body ([@B12], [@B40], [@B41]). Removal of the superior cervical ganglia can cause loss of vasoconstriction control of brain and pituitary blood vessels ([@B47]), changes in cerebrospinal fluid production from the choroid plexus ([@B48]), and other central effects in response to partial sympathetic denervation ([@B49]). Moreover, abolition of the peripheral sympathetic innervation of the brain by SCGx is associated with several neuroendocrine changes in mammals, which include the disruption of water balance ([@B37]), and the alteration of normal photoperiodic control of reproduction ([@B50], [@B51]).

As previously mentioned, the mammalian circadian system is held in synchrony by the SCN through endocrine and autonomic outputs ([@B52], [@B53]). One of the mayor endocrine cues is the pineal hormone melatonin. Its synthesis and release is driven by the SCN through a multisynaptic pathway relaying in the SCG ([@B54], [@B55]). This interaction determines the rhythmic production of the hormone, whose day--night profile is modulated by daylength ([@B23]), encoding photoperiodic changes in the metabolic state ([@B56]).

Previous evidences have shown that SCGx decreases the secretion of melatonin and suppresses its rhythm ([@B32], [@B33]). The relationship between melatonin and the circadian control of metabolism has been demonstrated before. Pinealectomy and melatonin administration or replacement ([@B57], [@B58]) significantly changes body weight, as well as glucose levels and its utilization in different tissues ([@B59]). In our model, we found decreased levels of glucose at ZT10, but a GTT showed no differences between SCGx and sham-operated animals. In contrast, pineal ablation in rats was shown to increase glucose levels ([@B57]).

Furthermore, leptin secretion is strongly associated with glucose and lipid metabolism, and has been shown to be modulated by melatonin ([@B60]). Moreover, the administration of melatonin in experiments conducted in rats and rabbits induced a reduction in body weight, serum lipids, adiposity, blood glucose, and insulin levels associated with the intake of a high-fat diet, suggesting a protective role of melatonin ([@B20], [@B61], [@B62]).

Taking into account our results, SCGx mimics the effect of pinealectomy on the neuroendocrine system only in some aspects, affecting several areas that include, but are not restricted to, the pineal gland. Although we cannot state that all SCGx-induced changes presented here are exerted *via* a suppressed pineal function, it is tempting to speculate that the diurnal timing of locomotion and feeding might be related to the lack of melatonin feedback to the circadian clock.

The importance of timed feeding and circadian physiology of metabolism has been extensively studied ([@B63], [@B64]). In this sense, an increased fat anabolism during daytime (i.e., the rest phase) due to food consumption at this time, may explain the lower levels of blood glucose, and lead to increased adiposity in the SCGx group. Previous studies showed that animals fed during the light phase exhibit an increased body weight and food consumption, alterations in leptin, insulin, corticosterone, glucose, and free fatty acid levels in plasma, fat accumulation, liver steatosis, and metabolic syndrome ([@B65]--[@B69]). These alterations arise from a completely reversed clock-gene expression in the liver, kidney, heart, and pancreas, without affecting SCN function ([@B9]).

On the other hand, SCGx rats exhibit significantly augmented serum corticosterone and adreno-corticotropin hormone levels, and a suppression of their rhythm ([@B35], [@B70]). Glucocorticoids (GCs) can stimulate the *de novo* synthesis of lipids ([@B71]). It has been reported that rats exposed to long-term treatment with GCs show a slower body weight gain, reduced food intake, and increased epididymal fat mass ([@B72]). Some of the effects reported here might be related to alterations in GC turnover that, in turn, could lead to the increase in FE and lipid accumulation. Indeed, the role of the sympathetic neuro-adipose connections in the regulation of lipolysis and body weight has been studied before ([@B73]). Sympathetic denervation leads to an increase in adipose tissue, while nerve stimulation results in fatty acid release, and sympathetic or ganglionic blockade inhibits the mobilization of lipids ([@B74]--[@B76]). Leptin production is also under the control of the sympathetic system ([@B77]), with participation of the SCG ([@B78]).

Regarding light synchronization, it has been demonstrated that pinealectomy accelerates the re-entrainment of rats to the new LD schedule ([@B79]--[@B82]). Moreover, in rodents, melatonin administration synchronizes free-running rhythm and accelerates re-entrainment after phase shifts of the LD cycles ([@B83]--[@B85]), and reinforces entrainment to shortened 22 h LD cycles in both SCGx and pinealectomized rats ([@B86]). We studied the effect of SCGx on the entrainment to the LD cycle and found no significant differences on period, phase angle, or total locomotor activity between SCGx and sham-operated animals. However, SCGx rats showed significant differences in activity during daytime (lights on). In addition, food intake analysis evidenced augmented food consumption during daytime, which may correlate with the activity bouts under the light phase.

Also, it was previously observed that bilateral removal of the SCG delays the synchronization of feeding rhythms with a newly imposed diurnal lighting regimen, but, again, the response to pinealectomy was different ([@B87]). In fact, the elimination of pineal rhythmicity cannot account for all of the effects of SCGx on photic entrainment of feeding and locomotor activity rhythms. It can be suggested that SCGx alters the sympathetic innervation of hypothalamic structures implicated in the neural control of feeding, affecting the diurnal rhythm of food intake.

Rhythms in metabolism are orchestrated by the SCN and other inputs from different areas of the hypothalamus, like the mediobasal region, which plays a significant role in metabolic homeostasis ([@B88]--[@B93]). Other areas, like the dorsomedial hypothalamus, have an important role as a component of the SCN-independent food-entrainable oscillator ([@B94]--[@B97]). The circadian regulation of body weight depends on the integration of multiple signals of several hypothalamic areas, including the SCN, the arcuate nucleus, the ventromedial hypothalamic nucleus, and the paraventricular nucleus, that control appetite and food intake, deposition of fat, and energy expenditure ([@B11], [@B53], [@B98]). Melatonin not only couples circadian cues to many body functions but might also be a key player in the regulation of basal metabolic rate ([@B99]), independently of other SCG-innervated territories, such as the hypothalamus. In this sense, the results shown in this work provide evidence suggesting that SCGx may be affecting metabolism by changing the feeding pattern (i.e., increasing feeding during daytime), acting over peripheral clocks without affecting the SCN.

In conclusion, these findings provide insights into the metabolic and diurnal rhythms of ganglionectomized rats. SCGx is not only a good model to study the circadian clock influence on neuroendocrine functions, but a reliable approach to investigate the relationship between the circadian system and metabolism, as well as the role of the SCG innervation in the synchronization of the master circadian clock with the peripheral clocks, especially the ones that drive metabolic variables.
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